extended-release oxycodone

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:drug opioid
gptkbp:abusePotential	high
gptkbp:activeIngredient	gptkb:oxycodone
gptkbp:approvedBy	gptkb:FDA 1995
gptkbp:ATCCode	N02AA05
gptkbp:brand	gptkb:OxyContin
gptkbp:contraindication	acute or severe bronchial asthma severe respiratory depression
gptkbp:controlledSubstanceSchedule	gptkb:Schedule_II_(US)
gptkbp:drugInteraction	gptkb:MAO_inhibitors gptkb:CNS_depressants CYP3A4 inhibitors CYP3A4 inducers
gptkbp:duration	12 hours
gptkbp:eliminationHalfLife	~4.5 hours (extended-release)
gptkbp:form	extended-release tablet
gptkbp:genericAvailable	yes
https://www.w3.org/2000/01/rdf-schema#label	extended-release oxycodone
gptkbp:indication	chronic pain
gptkbp:legalStatus	prescription only
gptkbp:manufacturer	gptkb:Purdue_Pharma
gptkbp:mechanismOfAction	mu-opioid receptor agonist
gptkbp:metabolism	liver
gptkbp:overdoseTreatment	gptkb:naloxone
gptkbp:pregnancyCategory	C (US)
gptkbp:prescriptionForm	gptkb:tablet
gptkbp:riskFactor	addiction overdose misuse withdrawal symptoms
gptkbp:routeOfAdministration	oral
gptkbp:sideEffect	nausea constipation drowsiness respiratory depression
gptkbp:storage	room temperature
gptkbp:bfsParent	gptkb:Remoxy
gptkbp:bfsLayer	8